Introduction
T-cell large granular lymphocytic (LGL) leukemia is a disease with chronic elevations of large granular lymphocytes for more than 6 months associated with a T-cell clone and often cytopenias.
1,2 Although well described in the 2008 WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 3 , the clinical and pathologic diagnosis often remains elusive, as patients can exhibit significant polyclonal or oligoclonal proliferations of LGLs in reactive conditions. [4] [5] [6] Because clonal T-cell receptor (TCR) gene rearrangements can be identified in patients without neoplastic conditions, 7 the detection of T-cell clonality is often not sufficient to predict whether an LGL proliferation is neoplastic or reactive. Therefore, predicting and defining patients with increased LGLs as a significant monoclonal, neoplastic proliferation remain difficult. Although prior studies have demonstrated distinct histologic features associated with T-LGL leukemia in the marrow 8 as well as novel TCR antibodies that can be used to define LGL leukemia, 9 relatively few studies have attempted to comprehensively and statistically define the specifics of non-TCR antigen expression by flow cytometry. 10, 11 As such, we performed a detailed retrospective review of 85 patients, at Stanford University Medical Center, with LGL expansions in their peripheral blood in an attempt to determine distinct flow cytometry patterns that are associated with T-LGL leukemia.
Patients and methods

Patients
Eighty-five consecutive patients with peripheral blood large granular lymphocytic expansions, T-cell clonality studies and adequate flow cytometry data who were evaluated at Stanford University Medical Center between 2003 and 2010 were included in this study. Cases were diagnosed with peripheral blood smear review together with clinical data and follow-up; non-clonal LGL proliferations (n ¼ 35), based on TCR gene rearrangement polymerase chain reaction studies (see below), as well as clonal T-LGL leukemia (n ¼ 50) were studied. Clinical parameters, hemogram data, and molecular and flow cytometry immunophenotyping results at the time of diagnosis were reviewed. Clinical follow-up information was obtained by retrospective review of electronic medical records. Peripheral blood smears with LGL differential cell counts were re-reviewed by Ohgami and Pereira. Criteria for a diagnosis of T-LGL leukemia required: persistence of absolute or relative numbers of LGLs, unexplained cytopenias and a clonal TCR rearrangement from peripheral blood or a bone marrow sample. Statistical analysis was performed using the Student paired t-test, Fisher's exact test, or a 1-way analysis of variance using Stata. This study was approved by Stanford's Institutional Review Board.
Flow cytometry
Direct multi-parameter flow cytometry was performed on a FACSCalibur cytometer (Becton Dickinson, San Jose, CA, USA) using commercially available antibodies (Supplementary Table 1 ). An analysis gate was selected to include the population in the CD45 þ /low-side scatter region. The percentage of events reactive with each monoclonal antibody was determined, setting thresholds with isotypic controls. A CD8 þ (dim)/ CD57 þ population was defined as a visually distinct grouping of events that comprised a cluster of 410% of T cells (Figure 2) . Loss of expression of CD2, CD5 and CD7 was defined as complete or partial loss of antigen expression on 420% of the T-cell population.
for TRG@ and/or TRB@ followed by differential fluorescence detection or using heteroduplex or GeneScan analysis.
12,13
Results
Clinical data
Clinical data are summarized in Table 1 . Fifty clonal T-LGL leukemia and thirty-five non-clonal LGL proliferation cases were identified. Of the non-clonal cases, 27 cases were oligoclonal and 8 were polyclonal (Table 1 and Figure 1 ). No significant differences in age, sex or autoimmune disease were seen between the two categories (all P40.3). However, clonal T-LGL leukemia cases had an average neutrophil count (ANC) significantly lower than non-clonal LGL proliferations (median ANC ¼ 1.58 vs 3.25 Â 10 9 /l; P ¼ 0.002). Other notable findings were that non-clonal expansions of LGLs were seen more frequently in patients with bone marrow transplantation (P ¼ 0.0059) consistent with previous reported studies. 14, 15 In addition, the percentage of LGLs was significantly higher in cases of T-LGL leukemia compared with non-clonal LGL proliferations (26.5 vs 18%; P ¼ 0.01), again in agreement with prior studies. 8 Finally, morphologic features such as size, granularity or homogeneity of the LGL population were unable to stratify cases into clonal T-LGL leukemia vs reactive LGL proliferations (Figure 1 ).
CD8 þ (dim)/CD57 þ populations are associated with clonal T-LGL leukemia and neutropenia
To study the nature of LGL expansions, we analyzed the flow cytometry patterns from these 85 patients from 2003 to 2010. Our review was notable, and it demonstrated that patients with distinct populations of CD8 þ (dim)/CD57 þ T cells ( Figure 2 ) more frequently had monoclonal T-cell rearrangements and clinical evidence of T-LGL leukemia (Po0.001; Table 2 ) as well as lower values when compared with cases without these distinct populations (median ANC ¼ 1.45 vs 3.19 Â 10 9 /l; P ¼ 0.0017; Table 2 ). Furthermore, patients with both a distinct CD8 þ (dim)/CD57 þ population by flow cytometry and a T-cell clone had even lower ANC values compared with those without both criteria (median ANC ¼ 1.41 vs 3.0 Â 10 9 /l; P ¼ 0.001).
These findings demonstrate that a specific, reproducibly identifiable population of T cells is seen in clinically notable cases of clonal T-LGL leukemia.
Complete or partial loss of CD5, and expression of CD16 are associated with clonal T-LGL leukemia; however, loss of CD7 expression is not significant
We additionally analyzed the expression patterns of other T-and NK-cell antigens (Table 3 ). Detailed studies demonstrated that loss of CD5 expression was not only significantly associated with clonal T-LGL leukemia compared with non-clonal LGL proliferations (26/50 vs 5/35; Po0.001), but also with neutropenia (median ANC 1.41 vs 2.70 Â 10 9 /l; P ¼ 0.002). Furthermore, cases with complete or partial loss of CD5 expression, together with a T-cell clone, had even lower ANCs compared with cases without these dual criteria (median ANC 1.40 vs 2.70 Â 10 9 /l; P ¼ 0.004). In contrast, CD2 and CD7 loss were not significantly associated with clonal T-LGL leukemia or cytopenias (Table 3) . Finally, expression of CD16 was significantly associated with T-LGL leukemia (P ¼ 0.01), but not with cytopenias. ) and (c) demonstrate distinct CD8 þ (dim)/CD57 þ populations which are circled in dotted lines; these cases were all monoclonal. Panels (d), (e) and (f) lack a distinct CD8 þ (dim)/CD57 þ group but do show a prominent CD8 þ /CD57 þ population with a spectrum of CD57 expression; these cases were oligoclonal or polyclonal. Distinct CD8 þ (dim)/CD57 þ populations together with loss of CD5 expression identify T-LGL leukemia cases with the most significant neutropenia Finally, we attempted to determine whether we could combine the findings of discrete CD8 þ (dim)/CD57 þ populations and CD5 loss to even further sub-stratify LGL cases. Understandably, cases with the dual criteria of a CD8 þ (dim)/CD57 þ population and CD5 loss, were significantly associated with clonal T-LGL leukemia compared with non-clonal LGL proliferations (19/50 vs 2/35; P ¼ 0.001). Interestingly, use of both criteria, a CD8 þ (dim)/CD57 þ population and CD5 loss, defined the most severe cases of neutropenia when compared with cases without both criteria (median ANC ¼ 1.32 vs 2.7 Â 10 9 /l; P ¼ 0.003). These findings suggest that the population of T cells with expression of CD57, loss of CD5 and dimmer expression of CD8 may be intrinsically linked to neutropenia.
Discussion
Proliferations of large granular lymphocytes are a relatively frequent finding in peripheral blood samples. 2 Whereas in many cases, these expansions of LGLs can be attributed to a reactive etiology, often a determination of a reactive expansion of T cells vs a significant neoplastic clonal expansion of T cells is difficult to distinguish.
Profound advancements concerning T-LGL leukemia have been made in particular with regards to large panels of antibodies against various isoforms of the TCR-V portion of the TCR; these panels seek to determine clonality by flow cytometry. 16, 17 However, although these antibodies are powerful diagnostic tools, many clinical laboratories do not have access to these panels (24 antibodies against the TCR-V), and complete coverage of the TCR repertoire is incomplete at B70% with these antibodies. As such, routine determination of clonality by flow cytometry is often difficult and expensive.
Other methodologies for determining aberrant populations of T cells and correlation with T-LGL leukemia have been proposed and some groups have described loss of CD5, loss of CD7 and expression of CD16 and CD56 as significant indicators of T-LGL leukemia. 10, 18 Others have detailed specific bone marrow immunohistochemical criteria for defining cases of T-LGL leukemia with detailed statistical analyses. 8 However, a statistically powered study of cases of LGL expansions to determine the significance of variations in antigen expression by flow cytometry has not been performed to date.
Here, we show that distinct patterns of antigen expression on T cells can be used to identify cases that are significantly associated with clonal T-LGL leukemia and significant neutropenia. Specifically, we demonstrate that distinct clusters of CD8 þ (dim)/CD57 þ T cells by flow cytometry are associated with clonal T-LGL leukemia as well as with neutropenia. Furthermore, we demonstrate that loss of CD5, partial or complete, is seen in association with clonal T-LGL leukemia as well as in association with neutropenia. Combination of these two parameters, CD8 þ (dim)/CD57 þ clusters and CD5 loss, continues to define cases of T-LGL leukemia and those with the most significant neutropenia. Although others have discussed CD56 expression in some cases of T-LGL leukemia, often with the most aggressive phenotypes, no cases were associated with a clinically aggressive course due to T-LGL leukemia in our study; furthermore, we did not find expression of this antigen to be significantly associated with cases of T-LGL leukemia vs reactive oligoclonal expansions of T cells. Nevertheless, we did find, as others have previously demonstrated, that expression of CD16 is seen more frequently in cases of T-LGL leukemia; 18 however, interestingly, expression of CD16 was not associated with lower neutrophil counts overall. Instead, by our results, CD16 might identify those cases, in which patients have T-LGL leukemia, but are less likely to suffer from clinically significant neutropenia. Finally, as others, we note that loss of CD7 is seen in many cases of T-LGL leukemia. However, though CD7 loss was seen slightly more frequently in cases of T-LGL leukemia vs reactive expansions (39 vs 24% respectively), statistical analyses did not find this difference to be significant (P ¼ 0.22). Therefore, CD7 loss does not appear to be a reliable variable to determine cases of clonal T-LGL leukemia vs reactive LGL proliferations.
Numerous studies have analyzed the nature of CD8 þ /CD57 þ T cells. Although this distinct subset represents a population of cytotoxic T cells with an effector phenotype, the significance of CD57 expression has been debated. Some studies have defined CD8 þ T cells with expression of CD57 as replicatively scenescent T cells, 19 whereas others demonstrate these cells to be effector cytotoxic T cells that are increased in infections or neoplasms and represent a chronically activated state. [20] [21] [22] [23] [24] Still, others have shown that expansions of CD8 þ /CD57 þ T cells are seen with increased frequency in the elderly, and they have postulated defects in immune system homeostasis leading to expansion of these T cells and diminished immune system surveillance. 25 Nonetheless, we are not aware of significant studies on T cells with the phenotype of CD8 þ (dim)/CD57 þ expression. Although we find an association between distinct populations of CD8 þ (dim)/CD57 þ T cells and neutropenia, the cause vs effect relationship between these cells and cytopenias is not defined. It is attractive to hypothesize that perhaps these atypical populations of T cells with dim CD8 expression and CD57 co-expression are directly or indirectly affecting hematopoietic cells through cytotoxic effects resulting in cytopenias; it is also possible that they are a secondary phenomenon and a marker of an underlying primary disorder of the bone marrow that is responsible for cytopenias. Indeed, some have offered such hypotheses and, in fact, found links between marrow failure syndromes, in particular myelodysplastic syndrome (MDS) and T-LGL leukemia. 26, 27 However, none of the cases in the current study were associated with MDS; therefore we cannot speculate on the possible relationship between CD8 þ (dim)/CD57 þ T cells and MDS. The significance of our criteria in cases with concurrent MDS and T-LGL leukemia deserves future study. Expression and loss of different T-cell and NK-cell antigens are noted below. Loss/lack of antigen expression in the cases of was noted as 420% of antigen loss (complete or partial) on T-cells. *Indicates significant P-value o0.05.
Finally, the use of TCR gene rearrangement studies on peripheral blood to determine clonality in patients with LGL proliferations is problematic. These studies often show clonal T-cell populations in asymptomatic older adults and, therefore, are not entirely specific for LGL leukemia. In the current study, we demonstrate that the combined identification of a T-cell clone and a CD8 þ (dim)/CD57 þ T-cell population and/or loss of CD5 on T cells is a more reliable predictor of neutropenia, and this combined approach may better define LGL leukemia than T-cell clonality studies alone.
In summary, we have identified distinct reproducible antigenic patterns in T-LGL leukemia that correlate with T-cell clonality and neutropenia. Specifically, the detection of CD8 þ (dim)/CD57 þ populations and loss of CD5 as seen by flow cytometry, significantly stratify and define clonal T-LGL leukemia patients with neutropenia. Furthermore, the identification of reproducible antigenic patterns of expression with accessible flow cytometry antibodies suggests a novel diagnostic methodology and supports T-LGL leukemia over reactive LGL proliferations.
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